Search

Displaying results 5031 - 5040 of 7452 in total
  1. Drug

    Etiracetam

    go.drugbank.com/drugs/DB11868
    Experimental

    Etiracetam is under investigation in clinical trial NCT01137110 (Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)).

  2. Drug

    OTX-2002

    go.drugbank.com/drugs/DB17246
    Investigational

    OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).

  3. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  4. Drug

    alpha-Hydroxylinoleic acid

    go.drugbank.com/drugs/DB16027
    Investigational

    alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).

  5. Drug

    Ribaxamase

    go.drugbank.com/drugs/DB16311
    Investigational

    Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).

  6. Drug

    Aviscumine

    go.drugbank.com/drugs/DB12684
    Investigational

    Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).

  7. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).

  8. Drug

    RS5441

    go.drugbank.com/drugs/DB33178
    Experimental

    RS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]

  9. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  10. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that...